Aspen Grove Capital’s VanEck Biotech ETF BBH Stock Holding History

Aspen Grove Capital’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$513K	Sell	2,522 -2,397	-49%	-$451K	0.07%	110
2026 Q1	$925K	Sell	4,919 -2,519	-34%	-$485K	0.18%	73
2025 Q4	$1.41M	Sell	7,438 -2,540	-25%	-$470K	0.24%	56
2025 Q3	$1.65M	Hold	9,978	–	–	0.28%	51
2025 Q2	$1.53M	Hold	9,978	–	–	0.26%	54
2025 Q1	$1.57M	Hold	9,978	–	–	0.3%	51
2024 Q4	$1.57M	Buy	9,978 +78	+0.8%	+$13.1K	0.33%	50
2024 Q3	$1.76M	Hold	9,900	–	–	0.39%	42
2024 Q2	$1.67M	Hold	9,900	–	–	0.39%	43
2024 Q1	$1.65M	Hold	9,900	–	–	0.47%	42
2023 Q4	$1.64M	Buy	9,900 +43	+0.4%	+$6.62K	0.5%	41
2023 Q3	$1.53M	Hold	9,857	–	–	0.57%	37
2023 Q2	$1.54M	Hold	9,857	–	–	0.5%	41
2023 Q1	$1.6M	Hold	9,857	–	–	0.7%	30
2022 Q4	$1.57M	Buy	+9,857	New	+$1.56M	0.73%	31

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Aspen Grove Capital's BBH Position: Q2 2026 in Review

Aspen Grove Capital reduced its VanEck Biotech ETF (BBH) stake by 49% in Q2 2026, selling an estimated $451K and leaving 2,522 shares worth $513K. The position accounts for 0.07% of the portfolio, ranked #110.

Aspen Grove Capital first reported a position in BBH in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.76M in Q3 2024. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Aspen Grove Capital held 2,522 shares of VanEck Biotech ETF worth $513K as of Q2 2026.
Aspen Grove Capital sold 2,397 VanEck Biotech ETF shares in Q2 2026, an estimated $451K.
VanEck Biotech ETF made up 0.07% of Aspen Grove Capital's portfolio in Q2 2026, its #110 holding.
Aspen Grove Capital first reported a position in VanEck Biotech ETF in Q4 2022 and has held it in 15 quarters since.
Aspen Grove Capital's VanEck Biotech ETF position peaked at $1.76M in Q3 2024.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Aspen Grove Capital's 13F filing for Q2 2026, filed 14 Aug 2026.